サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1679410

前立腺がん治療の市場規模、シェア、動向分析レポート：薬剤クラス別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
前立腺がん治療の市場規模、シェア、動向分析レポート：薬剤クラス別、流通チャネル別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年02月28日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

前立腺がん治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の前立腺がん治療市場規模は2030年までに220億米ドルに達する見込みです。

同市場は、2025～2030年にかけてCAGR 8.6％で拡大すると予測されています。同市場の成長は、前立腺がんの有病率の上昇、ひいては新規治療に対する需要の増加に起因しています。例えば、2022年のACSによると、前立腺がんは世界で26万8,490人が新たに発症し、3万4,500人が死亡すると予想されています。前立腺がんは、男性のおよそ8人に1人が生涯のどこかで罹患し、高齢の男性に多く見られます。

政府の資金援助が急増し、知識を高めるための官民の取り組みが活発化し、一般市民の間で医薬品の入手可能性に関する認識が高まっていることが、市場の成長を加速させると予測されます。さらに、従来の方法よりもオンラインで医薬品を購入することへの嗜好の高まり、インターネット利用者の増加、オンライン薬局に関する意識の高まりは、治療導入率を高めると予想されます。

米国がん協会によると、2022年、前立腺がんは米国の男性人口における死因の第2位となっており、約41人に1人が前立腺がんで死亡しています。前立腺がんは死に至る病気ではあるが、この病気による死亡率は低いです。支援的な規制状況が利用可能であることは、複数回の治療で治癒しなかった患者のための精密医療である177Lu-PSMA-617のような新規製品の採用を促進すると予想されます。この製品は2022年3月にmCRPCの治療としてFDAの承認を取得しました。

標的療法や生物学的療法、化学療法、ホルモン療法は、この疾患の治療に用いられる方法の一部です。標的療法やその他の免疫療法のコストが高いことが、世界市場の大きな制約になると予測されています。新興国市場では、治療領域における技術の進歩に対する認識が低いことが、市場抑制要因になると予想されます。

UCLのMRC Clinical Trials Unitなどの研究機関では、新たな臨床検査が実施されています。同ラボが2022年6月に発表した紙製によると、前立腺がんの二次がん患者にはドセタキセルのような化学療法が有効であり、生存率は39%向上しています。これらの研究は、前立腺がん患者に個別化医療のアプローチを提供し、副作用をより少なくする、より効果的な方法を生み出しています。

前立腺がん治療市場レポートハイライト

  • 薬剤クラス別では、ホルモン療法が最大のシェアを占め、病態を完全に治療するための入手可能性と効率的な作用機序により、急成長が期待されます。
  • Xtandi薬剤は、同薬剤の高い採用率と長期間の使用により、予測期間中に最も速い速度で成長すると予想されます。
  • 北米は2024年に市場を席巻し、同地域における前立腺がんの有病率の増加と前立腺がん治療製品に対する強いニーズにより、最も急成長する地域と予想されます。
  • 同市場で事業を展開する新興国市場の主要企業は、需要を満たし効率的な治療オプションを提供するため、新規製品の開発に注力しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 前立腺がん治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析

第4章 前立腺がん治療市場：薬剤クラスビジネス分析

  • 薬剤クラス市場シェア、2024年と2030年
  • 薬剤クラスセグメントダッシュボード
  • 市場規模と予測と動向分析、薬剤クラス別、2018～2030年
  • ホルモン療法
  • 化学療法
  • 免疫療法
  • 標的療法
  • その他

第5章 前立腺がん治療市場：流通チャネルビジネス分析

  • 流通チャネル市場シェア、2024年と2030年
  • 流通チャネルセグメントダッシュボード
  • 市場規模と予測と動向分析、流通チャネル別、2018～2030年
  • 病院薬局
  • ドラッグストアと薬局
  • オンライン薬局

第6章 前立腺がん治療市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 国別、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 国別、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Johnson & Johnson Services, Inc.
    • Astellas Pharma Inc.
    • Eli Lilly and Company
    • Sanofi
    • Ipsen Pharma
    • Bayer AG
    • AstraZeneca
    • Bausch Health Companies Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global prostate cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 North America prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 US prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 US prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Canada prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Mexico prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 UK prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 UK prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Italy prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Italy prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Spain prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Spain prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Norway prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Denmark prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 Denmark prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Sweden prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Japan prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Japan prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 China prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 China prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 India prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 India prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Australia prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Australia prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 South Korea prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 South Korea prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Thailand prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Latin America prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Brazil prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Argentina prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 South Africa prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 UAE prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 UAE prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prostate Cancer Therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class and distribution channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Prostate cancer therapeutics market dynamics
  • Fig. 12 Prostate cancer therapeutics market: Porter's five forces analysis
  • Fig. 13 Prostate cancer therapeutics market: PESTLE analysis
  • Fig. 14 Prostate cancer therapeutics market: Drug class segment dashboard
  • Fig. 15 Prostate cancer therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 16 Hormonal therapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Prostate cancer therapeutics market: Distribution channel segment dashboard
  • Fig. 22 Prostate cancer therapeutics market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 23 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 24 Drug stores & retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 25 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 26 Prostate cancer therapeutics market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 France country dynamics
  • Fig. 42 France prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 China country dynamics
  • Fig. 57 China prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 India country dynamics
  • Fig. 59 India prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework
目次
Product Code: GVR-1-68038-925-8

Prostate Cancer Therapeutics Market Growth & Trends:

The global prostate cancer therapeutics market size is expected to reach USD 22.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2025 to 2030. The growth of the market is attributed to the escalating prevalence of prostate cancer which in turn increases the demand for novel therapeutics. For instance, as per the ACS in 2022, prostate cancer is expected to have 268,490 new cases and lead to the death of 34,500 people worldwide. It affects roughly one out of every eight men at some point in their lives and is more common in older men.

A surge in government funding and increased public and private sector initiatives to enhance knowledge, and awareness about the availability of medicines amongst the public are projected to accelerate market growth. Furthermore, a rising preference for online drug purchasing over traditional methods, an increase in the number of internet users, and a rise in awareness regarding online pharmacies are expected to enhance the treatment adoption rate.

As per the American Cancer Society, in 2022, prostate cancer is the second leading cause of death in the male population of the U.S. Around one man in every 41 dies from prostate cancer. Although prostate cancer is a deadly disease, the mortality rate from the disease is low. The availability of a supportive regulatory landscape is expected to drive the adoption of novel products such as 177Lu-PSMA-617, which is precision medicine for patients that have not been cured with multiple rounds of treatment. The product received FDA approval in March 2022 for the treatment of mCRPC.

Targeted and biological therapy, chemotherapy, and hormonal therapy are some of the methods used to treat the condition. The high cost of targeted therapies and other immunotherapies is projected to act as a significant limitation on the global market. Low awareness of technological advancements in the therapeutic area in developing countries is expected to become a restrain for the market.

New trials are being conducted by institutes such as MRC Clinical Trials Unit at UCL. A June 2022, publication by the institute highlights secondary cancer tumor type of prostate cancer patients are benefited more from the use of chemotherapy such as docetaxel with an enhanced survival rate of 39%. These studies are creating a more effective way of providing a personalized medicine approach to prostate cancer patients so that they experience fewer side effects.

Prostate Cancer Therapeutics Market Report Highlights:

  • By drug class, the hormonal therapy segment held the largest share and is expected to be the fastest-growing segment due to the availability and efficient mechanism of action for treating the diseased condition completely
  • Xtandi drug is expected to grow at the fastest rate over the forecast period due to the high adoption of the drug and usage of the drug for longer periods of time
  • North America dominated the market in 2024 and is anticipated to be the fastest-growing region owing to an increase in the disease's prevalence, and a strong need for prostate cancer therapeutic products in the region
  • Key market players operating in the market are focusing on developing novel products to meet the demand and provide efficient treatment options

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Prostate Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Prostate Cancer Therapeutics Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Hormonal Therapy
    • 4.4.1. Hormonal Therapy Market, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Targeted Therapy
    • 4.7.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Prostate Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Drug Stores & Retail Pharmacies
    • 5.5.1. Drug Stores & Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6. Prostate Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Johnson & Johnson Services, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Astellas Pharma Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Eli Lilly and Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Ipsen Pharma
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bayer AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Bausch Health Companies Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Merck & Co., Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Pfizer Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives